<a href=Bayer” height=”240″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/Main/rosacea.jpg” style=”padding: 10px” width=”228″ />

Bayer HealthCare has obtained approval from the US Food and Drug Administration (FDA) for its Finacea (azelaic acid) Foam, 15% to treat inflammatory papules and pustules of mild to moderate rosacea.

Papulopustular rosacea is a skin disease, which causes inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead.

Bayer HealthCare consumer care division innovation, research and development head Dr John O’Mullane said: "With the FDA’s approval of Finacea Foam, we can now offer patients suffering from rosacea in the US a new treatment option.

"This demonstrates Bayer’s continued commitment to delivering innovation that meets the preferences and needs of patients with mild to moderate rosacea."

"We can now offer patients suffering from rosacea in the US a new treatment option.."

Approval was based on results of two pivotal clinical trials that demonstrated the efficacy and safety of Finacea Foam compared against foam vehicle (without the drug azelaic acid) in the topical treatment of papulopustular rosacea.

The two multicentre, double-blind and vehicle-controlled clinical trials randomised the subjects in a 1:1 ratio to receive either azelaic acid foam, 15% or its foam vehicle twice-daily for 12 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Safety and tolerability have been assessed during the full 16-week study course, while the efficacy endpoints were evaluated at the end of the 12-week treatment period.

In the two studies, treatment with Finacea Foam resulted in a higher investigator’s global assessment (IGA) success rate compared with vehicle control, as well as greater reduction in the mean nominal change of inflammatory lesion count from baseline to the end of the 12-week treatment period, said the company.

The company plans to provide Finacea Foam through prescription in the US from the next month.

Image: Acne rosacea on face. Photo: courtesy of RicHard-59.